GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » IVERIC bio Inc (NAS:ISEE) » Definitions » Asset Turnover

IVERIC bio (IVERIC bio) Asset Turnover : 0.00 (As of Mar. 2023)


View and export this data going back to 2013. Start your Free Trial

What is IVERIC bio Asset Turnover?

Asset Turnover measures how quickly a company turns over its asset through sales. It is calculated as Revenue divided by Total Assets. IVERIC bio's Revenue for the three months ended in Mar. 2023 was $0.00 Mil. IVERIC bio's Total Assets for the quarter that ended in Mar. 2023 was $640.12 Mil. Therefore, IVERIC bio's Asset Turnover for the quarter that ended in Mar. 2023 was 0.00.

Asset Turnover is linked to ROE % through Du Pont Formula. IVERIC bio's annualized ROE % for the quarter that ended in Mar. 2023 was -57.11%. It is also linked to ROA % through Du Pont Formula. IVERIC bio's annualized ROA % for the quarter that ended in Mar. 2023 was -45.14%.


IVERIC bio Asset Turnover Historical Data

The historical data trend for IVERIC bio's Asset Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

IVERIC bio Asset Turnover Chart

IVERIC bio Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Asset Turnover
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

IVERIC bio Quarterly Data
Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23
Asset Turnover Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of IVERIC bio's Asset Turnover

For the Biotechnology subindustry, IVERIC bio's Asset Turnover, along with its competitors' market caps and Asset Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


IVERIC bio's Asset Turnover Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, IVERIC bio's Asset Turnover distribution charts can be found below:

* The bar in red indicates where IVERIC bio's Asset Turnover falls into.



IVERIC bio Asset Turnover Calculation

Asset Turnover measures how quickly a company turns over its asset through sales.

IVERIC bio's Asset Turnover for the fiscal year that ended in Dec. 2022 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (A: Dec. 2022 )/( (Total Assets (A: Dec. 2021 )+Total Assets (A: Dec. 2022 ))/ count )
=0/( (389.358+666.823)/ 2 )
=0/528.0905
=0.00

IVERIC bio's Asset Turnover for the quarter that ended in Mar. 2023 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (Q: Mar. 2023 )/( (Total Assets (Q: Dec. 2022 )+Total Assets (Q: Mar. 2023 ))/ count )
=0/( (666.823+613.407)/ 2 )
=0/640.115
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies with low profit margins tend to have high Asset Turnover, while those with high profit margins have low Asset Turnover. Companies in the retail industry tend to have a very high turnover ratio.


IVERIC bio  (NAS:ISEE) Asset Turnover Explanation

Asset Turnover is linked to ROE % through Du Pont Formula.

IVERIC bio's annulized ROE % for the quarter that ended in Mar. 2023 is

ROE %**(Q: Mar. 2023 )
=Net Income/Total Stockholders Equity
=-288.916/505.8515
=(Net Income / Revenue)*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-288.916 / 0)*(0 / 640.115)*(640.115/ 505.8515)
=Net Margin %*Asset Turnover*Equity Multiplier
= %*0*1.2654
=ROA %*Equity Multiplier
=-45.14 %*1.2654
=-57.11 %

Note: The Net Income data used here is four times the quarterly (Mar. 2023) net income data. The Revenue data used here is four times the quarterly (Mar. 2023) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** The ROE % used above is for Du Pont Analysis only. It is different from the defined ROE % page on our website, as here it uses Net Income instead of Net Income attributable to Common Stockholders in the calculation.

It is also linked to ROA % through Du Pont Formula:

IVERIC bio's annulized ROA % for the quarter that ended in Mar. 2023 is

ROA %(Q: Mar. 2023 )
=Net Income/Total Assets
=-288.916/640.115
=(Net Income / Revenue)*(Revenue / Total Assets)
=(-288.916 / 0)*(0 / 640.115)
=Net Margin %*Asset Turnover
= %*0
=-45.14 %

Note: The Net Income data used here is four times the quarterly (Mar. 2023) net income data. The Revenue data used here is four times the quarterly (Mar. 2023) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Therefore, it is a good sign if a company's Asset Turnover is consistent or even increases. If a company's asset grows faster than sales, its Asset Turnover will decline, which can be a warning sign.


IVERIC bio Asset Turnover Related Terms

Thank you for viewing the detailed overview of IVERIC bio's Asset Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.


IVERIC bio (IVERIC bio) Business Description

Traded in Other Exchanges
N/A
Address
8 Sylvan Way, Parsippany, New Jersey, USA, 07054
IVERIC bio Inc is a biopharmaceutical company focused on the discovery and development of novel treatment options for retinal diseases with significant unmet medical needs. The company is developing both therapeutic product candidates for age-related retinal diseases and gene therapy product candidates for orphan inherited retinal diseases, or IRDs.
Executives
Keith Westby officer: SVP & COO ONE UNIVERSITY SQUARE DRIVE, SUITE 280, PRINCETON NJ 08540
David Francis Carroll officer: SVP, CFO and Treasurer ONE UNIVERSITY SQUARE DRIVE, SUITE 280, PRINCETON NJ 08540
Glenn Sblendorio director 3 TIMES SQAURE, 12TH FLOOR, NEW YORK NY 10036
Christopher Paul Simms officer: Senior Vice President, CCO FIVE PENN PLAZA SUITE 2372, NEW YORK NY 10001
Anthony S Gibney officer: EVP, Chief Business Officer C/O ACHILLION PHARMACEUTICALS, INC., 300 GEORGE STREET, NEW HAVEN CT 06511
Calvin W. Roberts director 6120 WINDWARD PARKWAY, SUITE 290, ALPHARETTA GA 30005
Christine Ann Miller director 5 PENN PLAZA, SUITE 2372, NEW YORK NY 10001
Pravin Dugel officer: EVP, Chief Strategy & Business C/O AERPIO PHARMACEUTICALS, INC., 9987 CARVER ROAD, CINCINNATI OH 45242
David R Guyer director, officer: Chief Executive Officer ONE PENN PLAZA, 19TH FLOOR, NEW YORK NY 10119
Mark S. Blumenkranz director C/O 1LIFE HEALTHCARE, INC., ONE EMBARCADERO CENTER, SUITE 1900, SAN FRANCISCO CA 94111
Adrienne L Graves director 125 STONE MOUNTAIN CIRCLE, NAPA CA 94558
Versant Venture Capital Iv, L.p. 10 percent owner ONE SANSOME STREET, SUITE 3630, SAN FRANCISCO CA 94104
Versant Ventures Iv, Llc 10 percent owner ONE SANSOME STREET, SUITE 3630, SAN FRANCISCO CA 94104
Versant Side Fund Iv, L.p. 10 percent owner ONE SANSOME STREET, SUITE 3630, SAN FRANCISCO CA 94104
Jane Henderson director C/O ELEVEN BIOTHERAPEUTICS, INC., 215 FIRST STREET, CAMBRIDGE MA 02142

IVERIC bio (IVERIC bio) Headlines

From GuruFocus

SHAREHOLDER ALERT: Weiss Law Investigates IVERIC bio, Inc.

By PRNewswire PRNewswire 05-02-2023